» Articles » PMID: 33502488

Association Between Current Medication Use and Progression of Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Overview
Specialty Rheumatology
Date 2021 Jan 27
PMID 33502488
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Use of specific medications may accelerate the progression of radiographic knee OA (RKOA). Our aim was to examine the effect of medication use on the progression of RKOA.

Methods: We used longitudinal data from the Osteoarthritis Initiative (OAI), an observational study of risk factors for knee OA. At baseline, we selected participants with RKOA (Kellgren-Lawrence grade ≥2) and excluded those with a history of knee-related injury/surgery and other musculoskeletal disorders. Current medication use (use/non-use in the previous 30 days) and radiographic medial minimum joint space width (mJSW) data were available at baseline and annually up to 96 months follow-up. We used random effects, panel regression to assess the association between current medication use (non-users as reference group) and change in mJSW.

Results: Of 2054 eligible participants, 2003 participants with baseline mJSW data were included [55.7% female, mean age 63.3 (s.d. 8.98) years]. Of seven medication classes, at baseline NSAIDs were the most frequently used analgesia (14.7%), anti-histamine (10.4%) use was frequent and the following comorbidity medications were used most frequently: statins (27.4%), anti-hypertensives (up to 15.0%), anti-depressant/anxiolytics/psychotropics (14.0%), osteoporosis-related medication (10.9%) and diabetes-related medication (6.9%). Compared with current non-users, current use of NSAIDs was associated with a loss of mJSW (b = -0.042, 95% CI -0.08, -0.0004). No other associations were observed.

Conclusions: In current users of NSAIDs, mJSW loss was increased compared with current non-users in participants with RKOA. Clinical trials are required to assess the potential disease-modifying effects of these medications.

Citing Articles

Supplementary Treatment for Alleviating Pain and Enhancing Functional Ability in Geriatric Patients with Osteoarthritis.

Aurelian S, Oancea C, Aurelian J, Mihalache R, Vladulescu-Trandafir A, Capisizu A Healthcare (Basel). 2025; 13(2).

PMID: 39857154 PMC: 11765481. DOI: 10.3390/healthcare13020127.


Exosomes of stem cells: a potential frontier in the treatment of osteoarthritis.

Wang X, Xu L, Wu Z, Lou L, Xia C, Miao H Precis Clin Med. 2025; 8(1):pbae032.

PMID: 39781279 PMC: 11705996. DOI: 10.1093/pcmedi/pbae032.


Exploring the Causal Relationship between Ibuprofen Use and Osteoarthritis Risk: A Mendelian Randomization Study.

Jian Y, Lyu Y, Hashemolhosseini S Biology (Basel). 2024; 13(9).

PMID: 39336175 PMC: 11428583. DOI: 10.3390/biology13090748.


Exploring the causal link among statin drugs and the osteoarthritis risk based on Mendelian randomization research.

Chen W, Sun Z, Xiong X, Tan H, Hu J, Liu C Front Genet. 2024; 15:1390387.

PMID: 39296542 PMC: 11408317. DOI: 10.3389/fgene.2024.1390387.


Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis: a prospective multi-cohort study over 4-to-5 years.

Salis Z, Sainsbury A Sci Rep. 2024; 14(1):6593.

PMID: 38504099 PMC: 10950850. DOI: 10.1038/s41598-024-56665-3.


References
1.
Shirinsky I, Shirinsky V . Effects of medication-treated diabetes on incidence and progression of knee osteoarthritis: a longitudinal analysis of the Osteoarthritis Initiative data. Rheumatol Int. 2017; 37(6):983-991. PMC: 5587503. DOI: 10.1007/s00296-017-3676-7. View

2.
Lo G, McAlindon T, Katz J, Driban J, Price L, Eaton C . Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. Clin Rheumatol. 2017; 36(9):2121-2128. PMC: 5709188. DOI: 10.1007/s10067-017-3656-z. View

3.
Ratzlaff C, Ashbeck E, Guermazi A, Roemer F, Duryea J, Kwoh C . A quantitative metric for knee osteoarthritis: reference values of joint space loss. Osteoarthritis Cartilage. 2018; 26(9):1215-1224. PMC: 6098736. DOI: 10.1016/j.joca.2018.05.014. View

4.
Kang K, Kim Y, Yi H, Kim J, Jung H, Kim I . Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. Int Immunopharmacol. 2013; 16(1):85-92. DOI: 10.1016/j.intimp.2013.03.020. View

5.
Mastbergen S, Jansen N, Bijlsma J, Lafeber F . Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther. 2005; 8(1):R2. PMC: 1526565. DOI: 10.1186/ar1846. View